DNMT1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using IL2RA mouse mAb against Jurkat (1), Cos7 (2), HCT116 (3) and NTERA-2 (4) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using DNMT1 mouse mAb with DAB staining.    

  
  

DNA methyltransferase 1 (DNMT1) is a critical enzyme responsible for maintaining DNA methylation patterns during replication by copying methylation marks onto newly synthesized DNA strands. This epigenetic regulation is essential for gene silencing, genomic stability, and X-chromosome inactivation. DNMT1 antibodies are indispensable tools in studying its role in these processes, enabling detection, localization, and functional analysis in various experimental setups.

DNMT1 dysregulation is linked to diseases such as cancer (where overexpression promotes tumorigenesis), neurodegenerative disorders (e.g., Alzheimer’s), and autoimmune conditions. Antibodies targeting DNMT1 facilitate research into its involvement in these pathologies by enabling techniques like Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and immunohistochemistry.

These antibodies typically recognize specific epitopes or domains (e.g., the N-terminal regulatory region or C-terminal catalytic domain), allowing researchers to investigate post-translational modifications or protein interactions. Validation across species (human, mouse, rat) and sample types (cell lysates, tissues) ensures broad applicability.

Recent studies also explore DNMT1's non-canonical roles, such as in DNA repair or cellular differentiation, further driving demand for high-specificity antibodies. However, challenges remain, including cross-reactivity with other DNMTs (e.g., DNMT3A/B) and variability in experimental conditions. Overall, DNMT1 antibodies are pivotal in advancing epigenetic research and therapeutic targeting of methylation-related diseases.